Prohibitin-TP01
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
DoseGear research brief
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Engineered adipose-vasculature-targeting peptidomimetic.
Experimental obesity treatment delivering a mitochondrial-disrupting, pro-apoptotic peptide to adipose endothelium.
Obese rhesus monkeys were studied over 28 days of subcutaneous treatment; renal tubular safety findings were also reported.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Primate Research Replication | 0.43 mg/kg | Once daily | SubQ |
| Dose-Finding (Research) | 0.10-0.75 mg/kg | Once daily (escalating tiers) | SubQ |
Reference cycle
28 days
Reference storage
Lyophilized: -20°C freezer; Reconstituted: 2-8°C refrigerated
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Reversal of obesity by targeted ablation of adipose tissue
Prohibitin/Annexin A2 Interaction Regulates Fatty-Acid Transport
Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
